CVB homepage

Even TAVR patients not treated using transfemoral access can typically go home the very next day. 

Hemal Gada, MD, cardiologist

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. 

The doctor is accused of using fake credentials for several months and performing approximately 50 procedures. This is the second time in recent months someone has been accused of impersonating a heart specialist and treating patients.

business launch

The new name will be familiar to anyone who knows the history of Medtronic's diabetes business.

Imagers reviewing flurpiridaz F-18 (Flyrcado) myocardial perfusion PET images. Image from GE Healthcare

The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.

money maze benjamin franklin reimbursement medicare

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.

Innovation at work

The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.

Sponsored by Medtronic

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.